Study highlights pharmacovigilance challenges in CAR T-cell therapies, suggests specific assessment criteria
Cases of secondary tumors have been reported as a possible adverse reaction to the treatment of certain blood cancers with CAR T-cells. A recent analysis of the cases reported to the ...
Healio10d
Real-world outcomes with bispecific T-cell engagers in lymphoma worse than pivotal trials
Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...